Interesting pre-clinical data also exist for the combination of insulin/IGF system inhibitors with other drugs, including the lipid modulator simvastatin in prostate cancer (161), the VEGF antibody bevacizumab in ovarian cancer (162), and methyl jasmonate in endometrial cancer (163). Here, IGF1 is linked to prostate cancer.